Author

Carleen A. Klumpp-Thomas

National Center for Advancing Translational SciencesORCID 0000-0002-6646-6132Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 1

Frequent Co-Authors

Craig Thomas· 2 shared Crystal G. McKnightiD· 2 shared Xiaohu Zhang· 2 shared Amy Funk· 1 shared Benjamin C. BrimiD· 1 shared Carolyn C. WoodroofeiD· 1 shared Cindy H. ChauiD· 1 shared David O. HollandiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Craig Thomas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 20, 2026

A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers

Meghri Katerji, Kailey N. Jackett, Maxine R. Rubin…·John Brognard

This study identifies compound #63 as a potent LZK inhibitor that suppresses tumor growth and enhances EGFR and PI3K pathway blockade in HNSCC and ESCC.

DOI 10.64898/2026.10.19.760245

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 7, 2026

Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer

Jessica D. Kindrick, Kinjal P. Bhadresha, Xiaohu Zhang…·William D. Figg

This study identifies co-inhibition of XPO1 and EIF4A1 as a therapeutic strategy for mCRPC, showing synergistic antitumor effects at reduced drug doses.

DOI 10.64898/2026.05.04.722693

humanproteomics

𝕏 PostBluesky